Pfizer Inc. (PFE)
Pre-Market:
- Business Wire
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
NEW YORK, October 04, 2022--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The study met its primary endpoint with a statistically significant and clinica
- Zacks
Should Investors Buy Bristol Myers Squibb Stock?
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
- Zacks
Pfizer (PFE) Gains But Lags Market: What You Should Know
Pfizer (PFE) closed the most recent trading day at $44.14, moving +0.87% from the previous trading session.
